All-cause mortality (time- to-event) First heart- failure-related hospital admission (time- to-event) Non-fatal stroke (time-to-event) All outcomes reported at 3.3 years Studies included in the IPD: - ANZ - BEST - CAPRICORN - CIBIS I - CIBIS II - CORPENICUS - MDC - MERIT-HF - US-HF - SENIORS Pre-defined sensitivity analysis excluding the results of the BEST trial (bucindolol vs placebo) Chronic Heart Failure Beta-blockers in heart failure and concomitant atrial fibrillation NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Study Intervention and comparison Population Outcomes Comments NYHA III: beta-blocker: Only unconfounded head-to-head trials with recruitment of more than 300 people and a planned follow-up of more than 6 months were eligible for inclusion in the IPD. was conducted by the authors of this IPD. These results were obtained directly from the authors and have been extracted in this review. 